Portal de Periódicos da CAPES

WNT5B drives osteosarcoma stemness, chemoresistance and metastasis

2024; Springer Science+Business Media; Volume: 14; Issue: 5 Linguagem: Inglês

10.1002/ctm2.1670

2001-1326

Rachel S. Perkins, Glenn Murray, Sarocha Suthon, Lindsey Davis, Nicholson B. Perkins, Lily B. Fletcher, Amanda Bozzi, Saylor L. Schreiber, Jianjian Lin, Steven J Laxton, Rahul R. Pillai, Alec J. Wright, Gustavo A. Miranda‐Carboni, Susan A. Krum,

Sarcoma Diagnosis and Treatment

Treatment for osteosarcoma, a paediatric bone cancer with no therapeutic advances in over three decades, is limited by a lack of targeted therapies. Osteosarcoma frequently metastasises to the lungs, and only 20% of patients survive 5 years after the diagnosis of metastatic disease. We found that WNT5B is the most abundant WNT expressed in osteosarcoma tumours and its expression correlates with metastasis, histologic subtype and reduced survival.